君实生物(01877)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01877 君实生物

午间休市 05-20 12:05:00

22.800

+0.200

+0.88%

最高23.480	最低22.600	成交量87.20万
今开23.240	昨收22.600	日振幅3.89%
总市值234.16亿	流通市值59.28亿	总股本10.27亿
成交额1,997万	换手率0.34%	流通股本2.60亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01877","market":"HK","secType":"STK","nameCN":"君实生物","latestPrice":22.8,"timestamp":1779249900004,"preClose":22.6,"halted":0,"volume":872000,"delay":0,"changeRate":0.008849557522123862,"floatShares":260000000,"shares":1027000000,"eps":-0.87,"marketStatus":"午间休市","change":0.2,"latestTime":"05-20 12:05:00","open":23.24,"high":23.48,"low":22.6,"amount":19966995,"amplitude":0.038938,"askPrice":22.86,"askSize":600,"bidPrice":22.78,"bidSize":600,"shortable":3,"etf":0,"ttmEps":-0.691,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779253200000},"marketStatusCode":3,"adr":0,"listingDate":1545580800000,"exchange":"SEHK","adjPreClose":22.6,"openAndCloseTimeList":[[1779240600000,1779249600000],[1779253200000,1779264000000]],"volumeRatio":0.624626,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688180","market":"SH","secType":"STK","nameCN":"君实生物-U","latestPrice":37.91,"timestamp":1779247794000,"preClose":37.65,"halted":0,"volume":8098000,"delay":0,"premium":"-47.68"}},"requestUrl":"/m/hq/s/01877","defaultTab":"news","newsList":[{"id":"2636424831","title":"君实生物：JS015单药在晚期实体瘤中首次人体研究已完成 联合治疗胃肠道肿瘤中II期临床研究在进行中","url":"https://stock-news.laohu8.com/highlight/detail?id=2636424831","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636424831?lang=zh_cn&edition=full","pubTime":"2026-05-19 17:09","pubTimestamp":1779181776,"startTime":"0","endTime":"0","summary":"【君实生物：JS015单药在晚期实体瘤中首次人体研究已完成 联合治疗胃肠道肿瘤中II期临床研究在进行中】君实生物（688180.SH）5月19日在投资者互动平台表示，JS015（DKK1单抗）单药在晚期实体瘤中的首次人体研究已经完成，联合治疗在胃肠道肿瘤中的II期临床研究正在进行中，相关临床数据请以公司公告或学术会议报告为准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605193742049795.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605193742049795.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1515","BK1161","BK1583","01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636352158","title":"君实生物：截至2025年12月31日，公司持有南京英派药业股份有限公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2636352158","media":"每日经济新闻","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636352158?lang=zh_cn&edition=full","pubTime":"2026-05-19 15:49","pubTimestamp":1779176985,"startTime":"0","endTime":"0","summary":"每经AI快讯，有投资者在投资者互动平台提问：尊敬的董秘，您好！贵司目前有投资英派药业的股份吗？如有收益何时能并入财报？对君实的业绩是否有影响？君实生物（688180.SH）5月19日在投资者互动平台表示，截至2025年12月31日，公司持有南京英派药业股份有限公司股份，具体财务影响请以公司未来定期报告为准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605193741912174.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605193741912174.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","BK1515","01877","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636352388","title":"君实生物：目前公司已建立多特异性抗体研发平台并正在积极开展相关药物研发工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2636352388","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636352388?lang=zh_cn&edition=full","pubTime":"2026-05-19 15:49","pubTimestamp":1779176978,"startTime":"0","endTime":"0","summary":"每经AI快讯，有投资者在投资者互动平台提问：请问公司今年有没有三抗管线进入临床？君实生物（688180.SH）5月19日在投资者互动平台表示，目前公司已建立多特异性抗体研发平台并正在积极开展相关药物研发工作。如有相关候选药物进入研发阶段，公司将严格按照相关规定及时履行信息披露义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605193741911594.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605193741911594.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01877","BK1515","BK1161","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636030884","title":"【券商聚焦】招银国际：AI有望改变创新药研发范式","url":"https://stock-news.laohu8.com/highlight/detail?id=2636030884","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636030884?lang=zh_cn&edition=full","pubTime":"2026-05-19 13:13","pubTimestamp":1779167581,"startTime":"0","endTime":"0","summary":"当前，监管框架持续完善，传统药企与AI原生公司加速合作，AI制药正处于从研发提效工具迈向创新药研发范式重构的转折期。AI重构药物研发全链条，早期效率红利已率先显现。传统创新药研发长期受困于高成本、长周期和低成功率，AI技术正在改变靶点发现、分子筛选与优化等关键环节的研发范式。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1981743","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348827113.USD","LU0315179316.USD","LU1226288170.HKD","02142","LU0348767384.USD","LU1719994722.HKD","01177","LU0140636845.USD","01801","CHAT","02616","LU1960683339.HKD","09995","LU1152091168.USD","IE00B031HY20.USD","BK1588","LU0067412154.USD","LU0456827905.SGD","LU0072913022.USD","LU0634319403.HKD","LU0456846285.SGD","LU0561508036.HKD","ARTY","LU2097828631.EUR","AIPO","09926","06185","BK1589","LU0856984785.SGD","LU1993786604.SGD","09688","06160","LU1303224171.USD","BK1161","LU0572944931.SGD","06978","159992","BK1583","01877","LU0417516738.SGD","LU1880383366.USD","02269","LU1226287792.SGD","LU1152091754.HKD","AGIX","SG9999002562.SGD","LU0516422952.EUR","IE00BPRC5H50.USD","LU0326950275.SGD","01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636044929","title":"国金证券：给予君实生物买入评级，目标价53.0元","url":"https://stock-news.laohu8.com/highlight/detail?id=2636044929","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636044929?lang=zh_cn&edition=full","pubTime":"2026-05-18 13:55","pubTimestamp":1779083716,"startTime":"0","endTime":"0","summary":"国金证券股份有限公司甘坛焕近期对君实生物进行研究并发布了研究报告《公司业绩拐点已至，IO联合ADC构筑价值壁垒》，给予君实生物买入评级，目标价53.0元。采用DCF估值法，给予目标价53.00元/股，首次覆盖，给予“买入”评级。　　风险提示　　药品销售不及预期；临床试验进展不及预期；临床数据不及预期最新盈利预测明细如下：该股最近90天内共有6家机构给出评级，买入评级6家；过去90天内机构目标均价为53.12。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051800015233.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636483820","title":"【券商聚焦】中信建投：创新药迎盈利兑现期 国内商业化与海外授权双轮驱动业绩增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2636483820","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636483820?lang=zh_cn&edition=full","pubTime":"2026-05-18 09:32","pubTimestamp":1779067963,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指，2026年上半年医药行业触底回暖，创新药迎来盈利兑现期，国内商业化与海外授权双轮驱动业绩增长，多家企业扭亏。26Q1对外授权总额超600亿美元，ADC、双抗等前沿赛道交易持续火热。2026年ASCO年会94项中国研究中选口头报告，依沃西单抗登上全体大会，标志着中国创新药全球学术影响力迈上新台阶。国内支付端医保谈判与商保目录合力支持真创新。建议关注创新药国际化、边际改善等结构性机会。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/NjdhYmE3ZDczMTc4NjgyMDYzMDA3NjI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NjdhYmE3ZDczMTc4NjgyMDYzMDA3NjI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1981512","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06160","01877","01093","SG9999002562.SGD","LU1242518857.USD","LU1152091168.USD","LU1688375341.USD","IE00B5MMRT66.SGD","LU1993786604.SGD","LU0417516738.SGD","06185","09688","06978","BK1588","LU0588546209.SGD","BK1574","LU1969619763.USD","LU0979878070.USD","LU0516422952.EUR","LU0456827905.SGD","LU2097828631.EUR","LU0348827113.USD","LU0561508036.HKD","601066","IE00BZ08YS42.EUR","IE00B0JY6N72.USD","02269","09926","LU0516423174.USD","LU1303224171.USD","LU2097828557.USD","02616","LU0039217434.USD","01177","09995","LU1152091754.HKD","02142","IE00BZ08YR35.GBP","BK1161","BK1141","LU0359202008.SGD","159992","LU2399975544.HKD","LU1226287875.USD","LU0326950275.SGD","IE00BZ08YT58.USD","LU1242518931.SGD","LU2097828474.EUR","01801","IE00B543WZ88.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635771583","title":"开源证券：首次覆盖君实生物给予买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2635771583","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635771583?lang=zh_cn&edition=full","pubTime":"2026-05-15 11:55","pubTimestamp":1778817352,"startTime":"0","endTime":"0","summary":"开源证券股份有限公司余汝意,聂媛媛近期对君实生物进行研究并发布了研究报告《公司首次覆盖报告：全面布局IO+ADC 2.0时代，争新一代实体瘤SOC》，首次覆盖君实生物给予买入评级。我们预计公司2026-2028年营业收入分别为32.48/42.22/54.89亿元，EPS分别为-0.04/0.44/1.04元，首次覆盖，给予“买入”评级。最新盈利预测明细如下：该股最近90天内共有6家机构给出评级，买入评级6家；过去90天内机构目标均价为53.12。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051500020133.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","01877","688180"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157562156","title":"异动解读 | 君实生物盘中大涨5.23%，一季度营收同比大增45%亏损大幅收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=1157562156","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157562156?lang=zh_cn&edition=full","pubTime":"2026-05-11 11:15","pubTimestamp":1778469317,"startTime":"0","endTime":"0","summary":"君实生物今日盘中股价大幅上涨5.23%，表现显著强于生物医药板块整体走势。消息面上，公司近期披露的一季度财报显示，其营收同比增长45.09%，归母净亏损同比收窄超过九成，同时研发投入占比显著下降，盈利能力得到明显改善。强劲的业绩基本面被视为支撑本次股价逆势上涨的主要因素。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634641196","title":"每周股票复盘：君实生物（688180）H股及A股股本无变动","url":"https://stock-news.laohu8.com/highlight/detail?id=2634641196","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634641196?lang=zh_cn&edition=full","pubTime":"2026-05-10 01:34","pubTimestamp":1778348051,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘，君实生物报收于39.36元，较上周的40.38元下跌2.53%。君实生物当前最新总市值404.11亿元，在生物制品板块市值排名4/51，在两市A股市值排名544/5200。本周关注点公司公告汇总：君实生物H股及A股股本与已发行股份本月无变动公司公告汇总上海君实生物医药科技股份有限公司截至2026年4月30日的证券变动月报表显示，公司H股和A股的法定/注册股本、已发行股份及库存股份数目均无变动。H股于港交所上市，A股于上交所科创板上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051000000316.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1515","688180","BK1583","01877","159982","399300","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633412512","title":"君实生物（688180）披露截至2026年4月30日证券变动月报表，5月7日股价上涨1.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633412512","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633412512?lang=zh_cn&edition=full","pubTime":"2026-05-07 22:21","pubTimestamp":1778163674,"startTime":"0","endTime":"0","summary":"截至2026年5月7日收盘，君实生物报收于40.5元，较前一交易日上涨1.58%，最新总市值为415.81亿元。近日，君实生物发布《截至2026年4月30日的证券变动月报表》公告。公告显示，截至2026年4月30日，公司H股和A股的法定/注册股本、已发行股份及库存股份数目均无变动。H股于港交所上市，A股于上交所科创板上市。当月未发生股份增减，公众持股量符合上市规则要求。公司确认相关发行事项已获董事会批准并遵守监管规定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050700041343.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["01877","BK1161","688180","BK1515","BK0239","BK1583","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132961330","title":"君实生物2026年4月股份变动月报表：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1132961330","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132961330?lang=zh_cn&edition=full","pubTime":"2026-05-07 18:43","pubTimestamp":1778150591,"startTime":"0","endTime":"0","summary":"上海君实生物医药科技股份有限公司于2026年5月7日公布了截至2026年4月30日止的股份变动月报表。报告期内，公司已发行股本和注册股本均未发生变动，股本结构维持稳定。根据公告披露，截至4月30日，公司注册股本合计人民币1,026,689,871元，包含260,295,700股H股和766,394,171股A股，均与上个月末保持一致。在股权激励方面，公司已于2025年9月29日批准采纳H股与A股股票期权激励计划，期权授予数量分别为13,210,000份和24,700,000份。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632427642","title":"每周股票复盘：君实生物（688180）一季度营收增45.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632427642","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632427642?lang=zh_cn&edition=full","pubTime":"2026-05-02 03:56","pubTimestamp":1777665370,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，君实生物报收于40.38元，较上周的39.8元上涨1.46%。本周，君实生物4月28日盘中最高价报43.0元。本周关注点来自业绩披露要点：君实生物2026年一季报显示，一季度主营收入7.26亿元，同比上升45.09%。股本股东变化股东户数变动截至2026年3月31日，君实生物股东户数为3.82万户，较2月28日增加212.0户，增幅0.56%。户均持股数量由上期的2.02万股下降至2.01万股，户均持股市值为69.93万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050200002535.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["01877","688180"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631754596","title":"盈利在即二级市场却“不买单”，君实生物(01877)能否踏出估值修复关键一步？","url":"https://stock-news.laohu8.com/highlight/detail?id=2631754596","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631754596?lang=zh_cn&edition=full","pubTime":"2026-04-29 17:49","pubTimestamp":1777456172,"startTime":"0","endTime":"0","summary":"4月27日，君实生物正式发布了2026Q1财报。在一季报披露次日，君实生物港股股价收涨4.45%，出现企稳反弹迹象。而在26Q1季度，君实生物实现收入7.26亿元，同比上涨45.09%，环比增长约5%;当期对应归母净利润同比大幅减亏91.24%。其中特瑞普利单抗当期销售收入为6.23亿元，2025年同期为4.47亿元，上涨了近40%。其中，JS207联合JS007一线治疗晚期肝细胞癌的II期研究是首次公布初步结果。而君实生物离新一轮估值修复与股价新高，或许只差重磅BD的临门一脚。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1436286.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1515","BK0239","688180","BK1161","01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129898375","title":"异动解读 | 君实生物盘中大涨5.06%，一季度业绩超预期亏损大幅收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=1129898375","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129898375?lang=zh_cn&edition=full","pubTime":"2026-04-28 09:43","pubTimestamp":1777340623,"startTime":"0","endTime":"0","summary":"君实生物今日盘中股价大幅上涨5.06%，引起了市场的广泛关注。消息面上，公司发布的2026年第一季度财报显示业绩表现强劲。报告期内，公司实现营业收入7.26亿元，同比增长45.09%。更为关键的是，归属于上市公司股东的净亏损约为2056.4万元，较去年同期的2.35亿元大幅收窄91.24%，显示出公司正快速迈向盈亏平衡点。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630347421","title":"港股君实生物绩后涨超3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630347421","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630347421?lang=zh_cn&edition=full","pubTime":"2026-04-28 09:40","pubTimestamp":1777340432,"startTime":"0","endTime":"0","summary":"4月28日，君实生物(01877.HK)绩后涨超3%，截至发稿，涨3.3%，报26.94港元，成交额923.16万港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604283721673874.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604283721673874.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK1583","BK1515","VXUS","BK4585","BK4588","688180","BK0239","01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630347551","title":"减亏91%、现金流转正！君实生物靠什么摆脱“输血”依赖？","url":"https://stock-news.laohu8.com/highlight/detail?id=2630347551","media":"21世纪经济报道","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630347551?lang=zh_cn&edition=full","pubTime":"2026-04-28 09:38","pubTimestamp":1777340280,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者季媛媛4月27日晚间，君实生物（1877.HK，688180.SH）披露2026年第一季度报告。财报数据显示，君实生物2026年第一季度实现营业收入7.26亿元，同比增长45.09%；归母净利润亏损2056.4万元，较上年同期亏损2.35亿元大幅减亏91.24%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604283721589710.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604283721589710.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK0239","BK1515","BK1583","01877","159399","688180"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630106703","title":"图解君实生物一季报：第一季度单季净利润同比增长91.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630106703","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630106703?lang=zh_cn&edition=full","pubTime":"2026-04-28 04:35","pubTimestamp":1777322100,"startTime":"0","endTime":"0","summary":"证券之星消息，君实生物2026年一季报显示，一季度公司主营收入7.26亿元，同比上升45.09%；归母净利润-2056.4万元，同比上升91.24%；扣非净利润-1.44亿元，同比上升40.03%；负债率56.97%，投资收益1.21亿元，财务费用3585.71万元，毛利率79.76%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800012415.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688180","01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111490627","title":"君实生物第一季度营收7.26亿元，经调整净利润0.43亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1111490627","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111490627?lang=zh_cn&edition=full","pubTime":"2026-04-27 22:36","pubTimestamp":1777300587,"startTime":"0","endTime":"0","summary":"君实生物发布2026年第一季度财报。报告期内，公司实现营业收入7.26亿元，同比增长45.09%。经调整净利润为0.43亿元，同比增长2.78亿元。同期经营活动产生的现金流量净额约0.58亿元，较上年同期的负值有所改善。研发投入为2.82亿元，占营业收入的38.90%，较上年同期的70.03%有所下降。核心产品特瑞普利单抗注射液报告期内在国内市场实现销售收入约6.23亿元，同比增幅39.37%，为营收增长贡献主要动力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"君实生物第一季度营收7.26亿元，经调整净利润0.43亿元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630539011","title":"君实生物(01877)建议采纳2026年A股员工持股计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2630539011","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630539011?lang=zh_cn&edition=full","pubTime":"2026-04-27 22:27","pubTimestamp":1777300020,"startTime":"0","endTime":"0","summary":"智通财经APP讯，君实生物(01877)发布公告，于2026年4月27日，董事会决议批准采纳公司2026年A股员工持股计划。2026年A股员工持股计划须经公司股东会审议批准后方能生效。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1434799.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01877","688180","159982","399300","BK1583","BK1161","BK1515","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117641748","title":"君实生物(01877)2025年收入同比增长28% 研发与国际化推进显著加速","url":"https://stock-news.laohu8.com/highlight/detail?id=1117641748","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117641748?lang=zh_cn&edition=full","pubTime":"2026-04-27 17:36","pubTimestamp":1777282601,"startTime":"0","endTime":"0","summary":"君实生物于报告期内在香港联交所与内地科创板保持双重上市结构，共发行1,026,689,871股，包括260,295,700股H股及766,394,171股A股。管理层则在董事会领导下具体执行经营与研发战略。2025年公司实现收入人民币24.98亿元，较2024年度增长28%，主要由于药品销售带动。全年研发开支为人民币13.84亿元，同比增加9%，主要因在研管线和临床开发进程持续投入。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"君实生物(01877)2025年收入同比增长28% 研发与国际化推进显著加速","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://junshipharma.com","stockEarnings":[{"period":"1week","weight":-0.124},{"period":"1month","weight":-0.2196},{"period":"3month","weight":0.0782},{"period":"6month","weight":-0.0798},{"period":"1year","weight":0.481},{"period":"ytd","weight":0.059}],"compareEarnings":[{"period":"1week","weight":-0.0209},{"period":"1month","weight":-0.0139},{"period":"3month","weight":-0.034},{"period":"6month","weight":-0.0015},{"period":"1year","weight":0.1057},{"period":"ytd","weight":0.0065}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海君实生物医药科技股份有限公司是一家主要从事创新驱动生物制药业务的中国公司。该公司主营业务为创新药物的发现、临床研究和开发。该公司的主要产品包括特立普珠单抗注射液、依替维单抗、阿达木单抗注射液等用于治疗恶性肿瘤、自身免疫系统疾病、慢性代谢疾病、神经系统疾病和感染性疾病的药物。该公司还从事重组人源化抗PCSK9单克隆抗体注射液等药物的临床研发。该公司主要为国内外市场提供产品。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.098181},{"month":2,"riseRate":0.75,"avgChangeRate":0.062525},{"month":3,"riseRate":0.75,"avgChangeRate":0.059343},{"month":4,"riseRate":0.875,"avgChangeRate":0.105939},{"month":5,"riseRate":0.375,"avgChangeRate":-0.013725},{"month":6,"riseRate":0.428571,"avgChangeRate":-0.018268},{"month":7,"riseRate":0.571429,"avgChangeRate":-0.014588},{"month":8,"riseRate":0.142857,"avgChangeRate":-0.040587},{"month":9,"riseRate":0.142857,"avgChangeRate":-0.026161},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.004518},{"month":11,"riseRate":0.571429,"avgChangeRate":0.043753},{"month":12,"riseRate":0.571429,"avgChangeRate":0.085319}],"exchange":"SEHK","name":"君实生物","nameEN":"JUNSHI BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"君实生物(01877)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供君实生物(01877)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"君实生物,01877,君实生物股票,君实生物股票老虎,君实生物股票老虎国际,君实生物行情,君实生物股票行情,君实生物股价,君实生物股市,君实生物股票价格,君实生物股票交易,君实生物股票购买,君实生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"君实生物(01877)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供君实生物(01877)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}